GSTM1 and stage 5 chronic kidney disease: Figure 4 shows changes in Hb, serum zinc, and ERI after zinc acetate hydrate administration in a 54-year-old man who was undergoing hemodialysis due to end-stage renal disease resulting from diabetic nephropathy. After zinc acetate hydrate administration, the ERI tended to decrease with the increase in Hb and serum zinc levels. Figure 5 shows changes in Hb, serum zinc, and ERI after zinc acetate hydrate administration in a 62-year-old man who was undergoing hemodialysis due to end-stage renal disease.